A multi-center, multi-queue, open Phase II clinical trial to evaluate the effectiveness and safety of Vebreltinib enteric capsules on late-stage non-small cell lung cancer with c-Met irregularity.
2022-09-26
1. Execution of letter of informed consent; 2. Male or female of age 18 and above;
View Details >
Vebreltinib PLB1004

China headquarters: 5th Floor, Block B, Wangjing Science and Technology Park, Lize Middle 2nd Road, Chaoyang District, Beijing.
American branch: 850 New Burton Road, Suite 201, City of Dover,County of Kent, State of Delaware
Phone: 010- 84148921
Email:
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.

京ICP备2020040683号-2